SURMOUNT-OSA misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The archive — 2026
Page 28 of 34 of this archive, newest first.
Why people actually stop, in the order they actually stop
The trials studied planned withdrawal. Almost nobody stops that way.
What SURMOUNT-3 tells us about maintenance, and what it does not
The commonest real-world strategy in this drug class is the least studied one.
Singapore health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
The quiet end of the online reseller trading as Adamant Research Supply
A proper account of an operation that existed, and of what closing it cost.
A supplier suspends shipping to New Zealand after 3 consecutive customs detentions
The route did not close because of a rule about peptides.
What changed at WXT in February, and what the company says prompted it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The withdrawal trials, read as designs rather than warnings
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
Freezing a reconstituted vial: the ice-water interface problem
An in-use period is established by a dedicated study on a specific formulation in a specific container at a specific concentration. Borrowing one from a marketed product is…
Halvard & Pike Apothecary of Portland, Maine closes after 6 years
A proper account of an operation that existed, and of what closing it cost.
Norway health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
KP names the synthesis and fill sites behind its catalogue
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Zhuhai export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Why a result on one vial says less than the trade needs it to
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
What the older diet-and-exercise trials found in the hip
The evidence base is one secondary analysis, several small studies and a large amount of extrapolation from bariatric surgery.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
India caps exenatide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
TRIUMPH-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Load, not cardio: the distinction the general advice keeps losing
What was supervised, at what frequency, at what intensity, and for how long.
Dose-limiting: a definition worth being strict about
An effect is dose-limiting when it prevents adequate intake, prevents normal activity, or produces a risk of its own. Discomfort alone is not the test.
Beta-arrestin, cAMP, and the part of dulaglutide’s mechanism nobody quotes
The receptor is expressed in more tissues than the popular account allows, and that is the whole story.
India pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Independent analysis puts a JEEP mazdutide lot at 98.9%, against 97.7% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
HJ names the synthesis and fill sites behind its catalogue
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A shortage listing ends. 23 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Same material, different gradients, different answers
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
One measurement, twenty companies, forty compounds
The Journal has read several hundred certificates from twenty companies. The number is almost always there; the method behind it almost never is.
The 9-day notice: how a compounding wind-down works in Ireland
The document is four pages. Three of them are about dates.
What a 9% rise in coupling-reagent prices does to a 5 mg vial
Follow the resin, not the catalogue.